Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Rob Jones

My Lucid journey from PMW to Head of Medical

Working in Medical Communications has never been about the nine to five. Fusing science and language in the service of both clients and patients, this is typically a fast paced...

Lucid Group Communications Limited

- PMLiVE

Creating patient support programmes that help patients thrive

By Laura Meade

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives CHMP recommendation for prevention of RSV disease in infants

Beyfortus reduced the incidence of medically attended lower respiratory tract infections caused by RSV

- PMLiVE

Otsuka and Aurinia’s Lupkynis granted EC approval as active lupus nephritis treatment

The treatment is for use in combination with mycophenolate mofetil

- PMLiVE

Roche’s Vabysmo receives EC approval to treat two leading causes of vision loss

60% of people treated with Vabysmo were able to extend treatment to every four months

- PMLiVE

Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment

A phase 3 trial demonstrated a statistically significant benefit in recurrence-free survival versus placebo

- PMLiVE

Tiziana announces Brigham and Women’s hospital will receive ALS Association grant

ALS affects as many as 30,000 people in the US

- PMLiVE

Patient support programmes: providing meaningful care when you dare to treat rare

By Aaron Hall

- PMLiVE

AstraZeneca’s COVID-19 treatment receives CHMP recommendation for use in EU

Evusheld provided statistically significant protection against progression to severe COVID-19 or death

- PMLiVE

Gilead’s Veklury WHO recommendation expanded for treatment of severe COVID-19

The antiviral showed a 17% lower relative risk of death or progression compared to standard of care

- PMLiVE

YouGov survey shows global health systems ‘unfit to cope’ with another pandemic

60% of healthcare professionals agree a lack of financial support leaves health systems vulnerable

- PMLiVE

Pfizer’s investigational meningococcal vaccine shows promise in phase 3 trial

There is currently no single vaccine available in the US to help protect against the main five serogroups

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links